Advanced & Metastatic Renal Cell Carcinoma
|
|
- Geoffrey Holmes
- 6 years ago
- Views:
Transcription
1 Advanced & Metastatic Renal Cell Carcinoma An Update G. Renzulli January
2 Overview of Cancers of the Kidney 2
3 Global Epidemiology 3
4 Global Epidemiology of Kidney Cancer 4 Globally, kidney cancer is the 15 th most common cancer As noted in the adjoining figure, kidney cancer is most prevalent in developed countries More common in men More common in elderly, but diagnosed at all ages More than 189,000 new cases are diagnosed worldwide each year In the US in 2008, it is estimated that more than 54,000 Americans will be diagnosed and about 13,000 will die Global Burden of Kidney Cancer in Men < 1.3 < 2.1 < 3.6 < 8.3 < 22.2 Age-standardized incidence/100,000 population 4
5 Types of Kidney Cancers 5
6 Types of Kidney Cancers 6 Kidney cancers distinguished by: Cell type Growth pattern Solitary or multiple masses in one or both kidneys Genetic characteristics 6
7 Malignant Kidney Tumors 7 Malignant kidney tumors: Frequency of Malignant Renal Tumors Renal cell carcinoma 90% Transitional cell carcinoma 5% to 10% Wilms tumor 5% Renal Cell Carcinoma Transitional Cell Carcinoma Wilms Tumor Renal Sarcoma Renal sarcoma <1% 7
8 Malignant Kidney Tumors 8 Renal Cell Carcinoma Sixth leading cause of cancer death in 2000 Men generally affected more than women The most common, accounts for 90% 5 main subtypes Clear cell, papillary, chromophobic, collecting duct, other Risk factors: smoking, obesity, heredity inter alia Symptoms usually asymptomatic until advanced may include hematuria, flank pain, and palpable flank mass 8
9 Renal Cell Carcinoma 9
10 Pathogenesis 10
11 Pathogenesis of RCC Renal cell carcinoma comprises approximately 2% of all malignancies, with diagnosis at a median age of 65 years The various subtypes of RCC have differing clinical, pathologic, and genetic characteristics Most cases are sporadic/non-inherited, but some are inherited 11 11
12 Risk factors for RCC Indicators of genetic predisposition: First-degree relative increases risk of RCC ~2- to 3-fold Diagnosis <40 years of age Bilateral or multifocal RCC Non-genetic risk factors: Smoking Exposure to toxic compounds Obesity Dialysis-associated cystic kidney disease Hypertension 12
13 RCC Epidemiology 13
14 Renal Cell Carcinoma Renal Cell Carcinoma The most common type of kidney cancer in adults Approximately 90% of adult kidney cancers are RCCs Approximately 85% are clear-cell tumours; the remainder comprise less common cell types Globally, RCC accounts for approximately 2% of all malignancies Incidence rates for kidney cancer are highest in developed countries, including North America, Australia, New Zealand and Europe Within Europe, RCC accounts for 3.1% of all cancers in males and 2.3% of all cancers in females 14
15 Renal Cell Carcinoma Mortality to incidence ratios with RCC are higher than any other urological malignancy, reflecting the aggressive nature of this cancer type Data from GLOBOCAN 2008 showed that, in Southern Africa, the incidence of cancer of the kidney was about 500 patients of which the mortality was 426!!! The 5-year prevalence was 1019 In Europe, 2006 mortality rates for patients with kidney cancer were 2.5 and 2.0% in males and females, respectively 15
16 South Africa Estimated incidence, mortality and 5-year prevalence: both sexes Cancer Incidence Mortality 5-year prevalence Number (%) ASR (W) Number (%) ASR (W) Number (%) Prop. Lip, oral cavity Nasopharynx Other pharynx Oesophagus Stomach Colorectum Liver Gallbladder Pancreas Larynx Lung Melanoma of skin Kaposi sarcoma Breast Cervix uteri Corpus uteri Ovary Prostate Testis Kidney Bladder Brain, nervous system Thyroid Hodgkin lymphoma Non-Hodgkin lymphoma Multiple myeloma Leukaemia All cancers excl. non-melanoma skin cancer Incidence and mortality data for all ages. 5-year prevalence for adult population only. ASR (W) and proportions per 100,000.
17 Renal Cell Carcinoma Due to a lack of standardised screening globally, and the fact that renal masses often remain asymptomatic and non-palpable until late in the disease course means that approximately 30% of individuals with RCC present with metastatic disease at first diagnosis Approximately 40% of individuals diagnosed with local tumours will subsequently develop metastatic disease Risk factors for RCC include smoking and obesity: other factors that have been shown to increase the risk of RCC include radiation therapy and chemical carcinogens, such as asbestos or organic solvents 17
18 Trends in RCC Incidence and Mortality 18 Incidence rates are rising 3 times faster than mortality rates Suggests improved overall survival over the last 25 years More cases of RCC being diagnosed in asymptomatic patients Incidence and US Death Rates (Kidney and Renal Pelvis Cancer) 1 Incidence Mortality Incidence rates are rising faster than mortality rates, suggesting an improvement in overall survival in patients with kidney cancer, including RCC, over 30 years spanning White ( ) Black ( ) API* ( ) AI/AN ( ) Hispanic ( ) * API- Asian/Pacific Islander AI/AN- American Indian/Alaska Native 18
19 GLOBAL GLOBOCAN DATA
20 Overall Survival The long-term survival of patients with advanced RCC remains low Stage 5-Year Overall Survival Stage I 90% to 95% Stage II 70% to 85% Stage III No lymph node mets: 45% to 65% Single lymph node met: 15% to 30% Stage IV Regional lymph node mets: 10% Distant met: <5% 20 20
21 Clinical Presentation 21
22 Presentation of Metastatic RCC Symptoms of metastatic disease Approximately 30% of patients have metastatic disease at presentation Sites of metastasis Most common is lung, in 75% Other common sites: lymph nodes, bone, liver, brain, adrenal gland, and the other kidney 22
23 Grading and Staging of RCC 23
24 The Fuhrman Nuclear Grading System for RCC Fuhrman Tumor Grade Nuclear Characteristics 1 Similar to normal renal cells 2 Larger than grade 1 tumors (~15 µm) with irregular morphology Nucleoli visible under high power (x400 magnification) 3 Larger nuclei than grade 2 (~20 µm) with marked variability in size/shape Large, prominent nucleoli evident even at low power magnification 4 Large, multi-lobed nuclei Similar to Grade 3 with heavy chromatin clumps 24
25 UICC and AJCC Consensus Report In 1997, consensus report recognized that the available evidence in the literature suggests that nuclear grade is a better prognostic indicator than other types of grading that do not use nuclear criteria. Recommended grouping grades 1 and 2 together Use of nuclear grading only for patients with clear cell and papillary RCC 25
26 Staging of RCC 26 Prognosis is directly related to stage, or extent to which the tumor has invaded other areas of the body Several tumor-staging systems have been developed to help predict response to treatment and survival in patients diagnosed with RCC The Robson system Developed in 1968 Stage I to stage IV RCC used to describe the extent of tumor spread beyond the renal capsule Robson system has largely been replaced by the TNM stage classification 26
27 Staging of RCC 27 The AJCC/TNM system Widely used Stage based on Tumour growth (T) Lymph node invasion (N) Extent of metastasis (M) Tumour stage correlates well with survival 27
28
29 5-Year Overall Survival by Stage and TNM Status Stage TNM 5-Yr Overall Survival, % I T1N0M II T2N0M III T3aN0M T3bN0M T3cN0M T1N1M T2N1M T3N1M IV T4 Any N M0 10 Any T N2 M0 10 Any T Any N M1 <5 29
30 RCC and its Subtypes RCC was the sixth leading cause of cancer death in 2000 RCC accounts for approximately 90% of kidney tumors There are 5 subtypes of RCC, all composed of different cell types Clear cell carcinomas Papillary/chromophilic carcinomas Chromophobic carcinomas Collecting duct carcinomas Other carcinomas Unclassified carcinomas Rare carcinomas 30
31 General Treatment Guidelines for Kidney Cancer Non-pharmacologic Treatments 31
32 2013 NCCN Guidelines: Non-pharmacologic Treatments Non-pharmacologic treatments If the tumor is resectable, surgery is the first step in treating RCC unless the patient is not a candidate for surgery because of poor health Surgery can sometimes cure RCC if the tumor is localized, however, most cases of RCC are discovered after the cancer has advanced or metastasized 32
33 Surgery Surgical resection is the only effective therapy for localized RCC Other treatment options may be considered if the patient is in poor physical health or elderly Choice of surgical procedure depends on the disease stage, health, and renal function of the patient Improved surgical techniques and an increase in incidentally found small tumors has allowed for the increased use of nephron-sparing surgery/partial nephrectomy in place of removal of the entire kidney/radical nephrectomy 33
34
35 General Treatment Guidelines for Kidney Cancer Pharmacologic Treatments 35
36 US Pharmacologic Treatments Overview Until the approval of targeted therapies, systemic treatment options for RCC consisted of immunotherapy with interleukin-2 /IL-2 and interferon-alfa/ifn-alfa or entry into clinical trials Novel molecularly targeted therapies, including several different inhibitors of tumor angiogenesis, have recently emerged as first- and second-line therapies in advanced RCC Tyrosine kinase inhibitors/tkis Mammalian target of rapamycin/mtor inhibitors Monoclonal antibodies IFN-alfa is not currently indicated for the treatment of RCC in the US 36
37 FDA Approval Dates for RCC Treatments Approval Dates for RCC Indications: FDA Interleukin 2/PROLEUKIN May 1992 Sorafenib/Nexavar December 2005 Sunitinib/Sutent January 2006 Temsirolimus/Torisel May 2007 Bevacizumab/Avastin in combination with IFN-alfa July 2009 Everolimus/Afinitor March
38 South African registrations and commercial availability of targeted agents for RCC IFN/IL2 Sorafenib (July 2007) Sunitinib (April 2008) Temsirolimus (May 2010) Everolimus (March 2012) Bevacizumab (May 2006) Pazopanib (Est Oct 2013) 38
39 Immunotherapy Works by triggering the immune system, which in turn destroys cancerous cells IL-2 and IFN-alfa, also called cytokines Used clinically to induce immune responses to RCCs IL-2 has been in use since the
40 Targeted Therapy Protein kinases are enzymes that activate or inactivate cell proteins or enzymes Protein kinase inhibitors including those that specifically target receptor tyrosine kinases, or tyrosine kinase inhibitors/tkis are used as treatment for malignant diseases In one study, a TKI was shown to improve efficacy in terms of increased objective tumor response rate: 31% sunitinib vs 6% IFN-alfa, and longer median progression-free survival in the treatment of RCC 40
41 mtor Inhibitors The mtor pathway is a critical mediator of cell metabolism, cell growth, and angiogenesis Two drugs that inhibit the mtor protein are: Temsirolimus Everolimus 41
42 Differences between Everolimus and Temsirolimus Everolimus Temsirolimus rapamycin analog 15 rapamycin prodrug 15 given orally 5 administered parenterally (intravenously) 5 42
43 Biological Therapy options in RCC Bevacizumab Sorafenib Sunitinib Temsirolimus Everolimus Pazopanib Company Genentech / Roche Bayer / Onyx Pfizer Wyeth Novartis GSK Agent Biological NCE NCE NCE NCE NCE Dosing Intravenous Oral bid Oral q.d.4wks/q 6wks Intravenous Oral q.d. Oral q.d. Molecular Targets VEGF A VEGF-R,Flt- 3,p38, Raf,c- Kit, PDGF-R VEGF- R,Flt-3, c- Kit, PDGF- R mtor inhibitor mtor inhibitor VEGF-R, c- Kit, PDGF-R RCC indication Combination with IFN 1 st line mrcc Cytokine refractory mrcc (not in the US where prior cytokine treatment is not required) Treatment of advanced / metastatic RCC 1 st line mrcc for high risk patient TKI failure mrcc Expected: Treatment of advanced / metastatic RCC mtor: (mammalian target of rapamycin) is a protein which in humans is encoded by the FRAP1 gene. mtor is a serine/ threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis, and transcription. mtor belongs to a related kinase protein family. 43
44 Explanation of Terms VEGFR: vascular endothelial growth factor receptor VEGFR are receptors for the protein vascular endothelial growth factor which is an important signaling protein involved in both vasculogenesis: the formation of the circulatory system and angiogenesis:the growth of blood vessels from pre-existing vasculature PDGFR: Platelet-derived growth factor receptors (PDGF-R) Are cell surface tyrosine kinase receptors for members of the PDGF family PDGF subunits A and B are important factors regulating cell proliferation, cellular differentiation, cell growth and development under normal circumstances and in many diseases including cancer There are two forms of the PDGF-R, alpha and beta - each encoded by a different gene C- kit : Mast/stem cell growth factor receptor (SCFR) Also known as proto-oncogene c-kit or tyrosine-protein kinase Kit or CD117, is a protein that in humans is encoded by the KIT gene CD117 is a proto-oncogene which means that overexpression or mutations of this protein can lead to cancer 44
45 NCCN Treatment Approach By Stage 45
46 Recommendations for patients with Stage I, Stage II, or Stage III RCC 44 Step 1. Surgical excision of the tumor Step 2. Observation or adjuvant therapy in a clinical trial Step 3. Follow up Every 6 months for 2 years then annually for 5 years: History and physical examination Comprehensive metabolic panel Lactate dehydrogenase/ldh level At 4 to 6 months, then as indicated: Chest and abdominal CT NCCN believes that the best management for any cancer patient is in a clinical trial. 46
47
48 Recommendations for patients with Stage IV RCC Classification Treatment Potentially surgically resectable solitary metastatic site Potentially surgically resectable primary* with multiple metastatic sites Medically or surgically unresectable* Nephrectomy + surgical metastasectomy Cytoreductive nephrectomy in select patients prior to systemic therapy First-line therapy First-line therapy *Individualized treatment based upon symptoms and extent of metastatic disease. 48
49
50 Relapse or Stage IV and Unresectable: Predominant Clear Cell Histology: First-line Therapy Clinical trial or Sunitinib (category 1) or Temsirolimus (category 1 for poor prognosis patients category 2B for selected patients of other risk groups) or Bevacizumab + IFN (category 1) or High dose IL-2 for selected patients or Sorafenib for selected patients and Best supportive care* NCCN believes that the best management for any cancer patient is in a clinical trial. *Best supportive care can include palliative RT, metastasectomy, or bisphosphonates for bony metastases. {National Comprehensive Cancer Network 2009 V2: pkid-2c} 50
51 Relapse or Stage IV and Unresectable: Predominant Clear Cell Histology: Subsequent Therapy Clinical trial preferred or Targeted therapy After TKI therapy Everolimus (category 1) Axitinib (category 1) Sorafinib (category 2A) Sunitinib (category 2A) Temsirolimus (category 2B) Bevacizumab (catagory 2B) Pazopanib (category 3) After Cytokine therapy Axitinib (category 1) Sorafinib (category 1) Sunitinib (category 1) Pazopanib (category 1) Temsirolimus (category 2A) Bevacizumab (category 2A) 51
52
53
54 Relapse or Stage IV and Unresectable: Predominant Clear Cell Histology: Subsequent Therapy Clinical trial preferred or Cytokine Therapy IL-2 (category 2B) Best Supportive Care * *Best supportive care can include palliative RT, metastasectomy, or bisphosphonates for bony metastases. {National Comprehensive Cancer Network 2009 V2: pkid-2c} 54
55 Relapse or Stage IV and Unresectable: Non Clear Cell Histology: First-line Therapy Clinical trial (preferred) Temsirolimus (category 1 for poor prognosis patients, category 2A for selected patients of other risk groups) or Sorafinib Sunitinib (category 1) or Pazopanib (category 3) or Erlotinib (category 3) or Axitinib (category 3) and Best supportive care* *Best supportive care can include palliative RT, metastasectomy, or bisphosphonates for bony metastases. {National Comprehensive Cancer Network 2009 V2: pkid-2c} 55
56
57 Agents represented on the SAOC Guidelines 57
58 Agents represented on the SAOC Guidelines 58
59 EAU Guidelines 59
60 EAU Guidelines for Localized and Metastatic RCC Localized RCC treatment consists of the following surgical procedures: Radical nephrectomy Partial nephrectomy/nephron-sparing surgery Laparoscopic nephrectomy Partial laparoscopic nephrectomy Metastatic RCC treatments: Surgery/tumour nephrectomy or metastectomy Radiation Pharmacologic therapy/immunotherapy, targeted therapy 60
61 Surgery for Metastatic RCC Only curative if all metastases are removed Tumor nephrectomy is recommended for metastatic RCC patients with good performance status when combined with IFN-alfa In patients with synchronous metastatic spread, metastasectomy should be performed where disease is resectable and the patient has a good performance status 61
62 Chemotherapy for Metastatic RCC RCCs are resistant to most chemotherapies Seems to be effective only if 5-fluorouracil/5FU is combined with immunotherapeutic agents Chemotherapy as monotherapy should not be considered effective in patients with mrcc 62
63 Pharmacologic Therapy for Metastatic RCC Immunotherapy Combination of cytokines, with or without additional chemotherapy, does not improve overall survival compared with monotherapy Targeted therapy approved for 1 st line or 2 nd line treatment Sorafenib: 2 nd line treatment Sunitinib: 1 st line therapy in good & intermediate-risk patients Temsirolimus: 1 st line treatment in poor-risk patients Bevacizumab: 1 st line option in combination with IFN-alfa2 Everolimus: approved for RCC/orphan status 63
64 Conclusions 64
65 Key Points If the tumor is resectable, surgery is the first step in treating RCC, unless the patient is not a candidate for surgery because of poor health IL-2 and IFN-alfa, also called cytokines, have been used clinically to induce immune responses to RCCs, but their use is often associated with toxicity Molecularly targeted therapies, including several different inhibitors of tumor angiogenesis, mtor inhibitors, and monoclonal antibodies, have emerged as 1 st line and 2 nd line therapies most commonly used in advanced RCC 65
66 Key Points Sorafenib and sunitinib are kinase inhibitors that target receptors involved in tumor angiogenesis Temsirolimus and everolimus inhibit mtor: a critical mediator of cell metabolism, cell growth and angiogenesis Bevacizumab is a monoclonal antibody that binds to VEGF and prevents it from activating its downstream pathway, which usually includes endothelial cell proliferation and blood vessel formation 66
67 Key Points NCCN Guidelines Stages I, II, and III RCC Step 1: Surgical excision Step 2: Observation or adjuvant therapy in a clinical trial Step 3: Follow up with lab tests and imaging studies Stage IV Nephrectomy and surgical metastasectomy in cases of potentially resectable solitary metastatic site Cytoreductive nephrectomy prior to targeted therapy in cases of potentially resectable primary with multiple metastatic sites If unresectable or recurrent, targeted therapy is recommended 67
68 Messages Ongoing evolution of treatment options Incremental improvements in outcomes Patient acceptance/preference to therapy i.e. tolerable and manageable side effects to ensure good compliance Pricing/cost will become more important as choice of available treatments increases 68
69 Questions 69
Guidelines on Renal Cell
Guidelines on Renal Cell Carcinoma (Text update March 2009) B. Ljungberg (Chairman), D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard, I.C. Sinescu Introduction Renal cell carcinoma
More informationGUIDELINES ON RENAL CELL CARCINOMA
GUIDELINES ON RENAL CELL CARCINOMA B. Ljungberg (chairman), D.C. Hanbury, M.A. Kuczyk, A.S. Merseburger, P.F.A. Mulders, J-J. Patard, I.C. Sinescu Introduction This EAU guideline was prepared to help urologists
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Health Technology Appraisal Cabozantinib for untreated locally advanced or metastatic renal cell carcinoma Final scope Remit/appraisal objective To appraise
More informationSAMPLE. Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to Reference Code: GDHC0004RCCDVR Publication Date: March 2012
Rencarex (Renal Cell Carcinoma)- Analysis and Forecasts to Reference Code: GDHC0004RCCDVR Publication Date: March 2012 The Renal Cell Carcinoma (RCC) Disease Therapeutics Market GlobalData s analysis suggests
More informationRenal Cell Cancer. Clinical case study 1 & 2. Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland
Renal Cell Cancer Clinical case study 1 & 2 Petri Bono MD PhD Helsinki University Hospital Helsinki, Finland 1 Case study 1 - RCC and Lung Metastases Case study 1: Patient History Male, 63 years old Mild
More informationTargeted and immunotherapy in RCC
Targeted and immunotherapy in RCC Treatment options Surgery (radical VS partial nephrectomy) Thermal ablation therapy Surveillance Immunotherapy Molecular targeted therapy Molecular targeted therapy Targeted
More informationMetastatic renal cancer (mrcc): Evidence-based treatment
Metastatic renal cancer (mrcc): Evidence-based treatment José M. Ruiz Morales, M.D. Hospital Médica Sur April 18th, 2018 4th ESO-ESMO Latin American Masterclass in Clinical Oncology Disclosures Consulting:
More informationMedical Management of Renal Cell Carcinoma
Medical Management of Renal Cell Carcinoma Lin Mei, MD Hematology-Oncology Fellow Hematology, Oncology and Palliative Care Virginia Commonwealth University Educational Objectives Background of RCC (epidemiology,
More informationRenal Parenchymal Neoplasms
Renal Parenchymal Neoplasms د. BENIGN TUMORS : Benign renal tumors include adenoma, oncocytoma, angiomyolipoma, leiomyoma, lipoma, hemangioma, and juxtaglomerular tumors. Renal Adenomas : The adenoma is
More informationGUIDELINES ON RENAL CELL CANCER
20 G. Mickisch (chairman), J. Carballido, S. Hellsten, H. Schulze, H. Mensink Eur Urol 2001;40(3):252-255 Introduction is characterised by a constant rise in incidence over the last 50 years, with a predominance
More informationHorizon Scanning Technology Briefing. Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma
Horizon Scanning Technology Briefing National Horizon Scanning Centre Sutent (Sunitinib) for first-line and adjuvant treatment of renal cell carcinoma August 2006: Updated October 2006 This technology
More informationImmunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game?
Immunotherapy versus targeted treatments in metastatic renal cell carcinoma: The return game? Sylvie NEGRIER MD, PhD Centre Léon Bérard, Lyon Université Lyon I IMMUNOTHERAPY: A LONG AND WIDING ROAD! WHERE
More informationComplex case Presentations
Complex case Presentations Case Presentations April 2016 Lisa M Pickering Case presentations: chromophobe renal carcinoma 60 year old man. ECOG PS 0 No significant comorbodities August 2009: L radical
More informationMultidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Multidisciplinary approach for renal cell carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 20 April, Antalya, Turkey RCC European Union 60.000 new diagnoses/year 26.000 Cancer related deaths
More informationOverview of 2010 Hong Kong Cancer Statistics
Overview of 2010 Hong Kong Cancer Statistics Cancer Registration in Hong Kong The Hong Kong Cancer Registry has since the 1960s been providing population-based cancer data for epidemiological research
More informationCODING STAGE: TNM AND OTHER STAGING SYSTEMS. Liesbet Van Eycken Otto Visser
CODING STAGE: TNM AND OTHER STAGING SYSTEMS Liesbet Van Eycken Otto Visser OVERVIEW PART I Introduction What is stage? Why stage? History and publications of TNM Classification Clinical and pathologic
More informationGuidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Renal Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationA Review in the Treatment Options for Renal Cell Cancer
A Review in the Treatment Options for Renal Cell Cancer Ali McBride, PharmD, MS BCPS, BCOP Clinical Coordinator Hematology/Oncology Department of Pharmacy The University of Arizona Cancer Center RENAL
More informationSustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma
JOURNAL OF CASE REPORTS 2015;5(1):280-284 Sustained Response to Temsirolimus in Chromophobe variant of Metastatic Renal Cell Carcinoma Chanchal Goswami, Aditi Mandal B. P. Poddar Hospital & Medical Research
More informationRCC in Adolescents and Young Adults (AYAs): Diagnosis and Management
RCC in Adolescents and Young Adults (AYAs): Diagnosis and Management Nicholas G. Cost, M.D. Assistant Professor, Department of Surgery, Division of Urology University of Colorado Cancer Center Fifteenth
More information1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.
History and Physical Case Scenario 1 45 year old white male presents with complaints of nausea, weight loss, and back pain. A CT of the chest, abdomen and pelvis was done on 12/8/12 that revealed a 12
More informationCABOMETYX (cabozantinib) oral tablet
CABOMETYX (cabozantinib) oral tablet Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific benefit plan. This Pharmacy
More informationThe plan. Overview of clinical trials Current clinical trials in renal cancer Future treatment of renal cancer
Relevant disclosure Bayer - consultancy GSK research funding, consultancy, speaker honoraria Novartis research funding Pfizer research funding, consultancy Roche / Genentech research funding, consultancy
More informationDavid N. Robinson, MD
David N. Robinson, MD Background and Treatment of mrcc Background ~ 64,770 new cases of kidney/renal pelvis cancers will be diagnosed in the US in 2012 with an estimated 13,570 deaths [1] ~ 75% are clear-cell
More informationRenal cell cancer: overview and immunochemotherapy
1 Renal cell cancer: overview and immunochemotherapy Vincent Khoo Introduction and epidemiology Kidney cancer is a relatively common urological cancer, accounting for approximately 2% of all adult cancers.
More informationOutcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The FH Memorial Medical Center s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures.
More informationManchester Cancer. Guidelines for the management of renal cancer
Guidelines for the management of renal cancer Approved by the urology pathway board September 2014 To be reviewed September 2016 Renal Cancer Guidelines 1. Introduction 1.1 Kidney cancer accounts for 3%
More informationHave Results of Recent Randomized Trials Changed the Role of mtor Inhibitors?
Have Results of Recent Randomized Trials Changed the Role of mtor Inhibitors? Bernard Escudier Institut Gustave Roussy Villejuif, France EIKCS Lyon April 2015 What is the current role of mtor inhibitors?
More informationSt. Dominic s Annual Cancer Report Outcomes
St. Dominic s 2017 Annual Cancer Report Outcomes Cancer Program Practice Profile Reports (CP3R) St. Dominic s Cancer Committee monitors and ensures that patients treated at St. Dominic Hospital receive
More informationRenal cell carcinoma (RCC)
Renal cell carcinoma (RCC) Introduction The most common solid renal tumor. Accounts for 2 3% of all adult malignancies. It is the 3 rd most common urological tumor in men and the 2 nd in women. It is th
More informationClinical Policy: Everolimus (Afinitor, Afinitor Disperz) Reference Number: PA.CP.PHAR.63
Clinical Policy: (Afinitor, Afinitor Disperz) Reference Number: PA.CP.PHAR.63 Effective Date: 01/18 Last Review Date: Coding Implications Revision Log Description The intent of the criteria is to ensure
More informationCancer in Estonia 2014
Cancer in Estonia 2014 Estonian Cancer Registry (ECR) is a population-based registry that collects data on all cancer cases in Estonia. More information about ECR is available at the webpage of National
More informationRENAL CELL CARCINOMA CLINICAL MANAGEMENT
page 1 / 5 page 2 / 5 renal cell carcinoma clinical pdf Haematological Malignancies. Waldenstrom's macroglobulinaemia Chronic myeloid leukaemia Newly diagnosed and relapsed mantle cell lymphoma Multiple
More informationRenal Cancer. By Jamie Calderwood
Renal Cancer By Jamie Calderwood ("Kidney Cancer")*1 ("What are the different types of kidney mass?")*2 What is it? Renal cancer is more commonly known as kidney cancer. Wilms tumor Another name for kidney
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016
pan-canadian Oncology Drug Review Final Clinical Guidance Report Nivolumab (Opdivo) for Metastatic Renal Cell Carcinoma September 1, 2016 DISCLAIMER Not a Substitute for Professional Advice This report
More informationSurgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute
Surgery of Renal Cell Carcinoma Axel Bex, MD, PhD The Netherlands Cancer Institute 23 March 2012, Sao Paulo, Brazil Surgery of RCC Locally confined (small) renal tumours Locally advanced disease Metastatic
More informationCancer survival in Hong Kong SAR, China,
Chapter 5 Cancer survival in Hong Kong SAR, China, 1996 2001 Law SC and Mang OW Abstract The Hong Kong cancer registry was established in 1963, and cancer registration is done by passive and active methods.
More informationReference No: Author(s) Approval date: June Committee. Operational Date: July Review:
Reference No: Title: Author(s) Systemic anti-cancer therapy (SACT) guidelines for renal cell cancer Dr Alison Clayton Consultant Medical Oncologist & Dr Jane Hurwitz Consultant Medical Oncologist, Cancer
More informationpan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013
pan-canadian Oncology Drug Review Final Clinical Guidance Report Axitinib (Inlyta) for metastatic Renal Cell Carcinoma March 7, 2013 DISCLAIMER Not a Substitute for Professional Advice This report is primarily
More information*
Introduction Cancer is complex, can have many possible causes, and is increasingly common. For the U.S. population, 1 in 2 males and 1 in 3 females is at risk of developing cancer in their lifetime. The
More informationAfinitor. Afinitor and Afinitor Disperz (everolimus) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.21.62 Subject: Afinitor Page: 1 of 9 Last Review Date: June 22, 2018 Afinitor Description Afinitor and
More information1. The metastatic cascade. 3. Pathologic features of metastasis. 4. Therapeutic ramifications. Which malignant cells will metastasize?
1. The metastatic cascade 3. Pathologic features of metastasis 4. Therapeutic ramifications Sir James Paget (1814-1899) British Surgeon/ Pathologist Paget s disease of Paget s disease of the nipple (intraductal
More informationOverview of 2009 Hong Kong Cancer Statistics
Overview of 2009 Hong Kong Cancer Statistics Cancer Registration in Hong Kong The Hong Kong Cancer Registry has since 1963 been providing population-based cancer data for epidemiological research and healthcare
More informationOverview of 2013 Hong Kong Cancer Statistics
Overview of 2013 Hong Kong Cancer Statistics Cancer Registration in Hong Kong The Hong Kong Cancer Registry (HKCaR) is a population-based cancer registry, collecting the basic demographic data, information
More informationMetastatic Renal Cancer Medical Treatment
Metastatic Renal Cancer Medical Treatment Bohuslav Melichar, M.D., Ph.D. Professor and Head Department of Oncology Palacký University Medical School and Teaching Hospital Olomouc, Czech Republic Peculiarities
More informationEAU GUIDELINES ON RENAL CELL CARCINOMA
EAU GUIDELINES ON RENAL ELL ARINOMA (Limited text update March 2016) B. Ljungberg (hair), K. Bensalah, A. Bex (Vice-chair), S. anfield, R.H. Giles (Patient Organisation Representative), M. Hora, M.A. Kuczyk,
More informationThe Therapeutic Landscape in Advanced Renal Cell Carcinoma
The Therapeutic Landscape in Advanced Renal Cell Carcinoma Cora Sternberg, MD, FACP Chairman, Department of Medical Oncology San Camillo-Forlanini Hospital Rome, Italy What best describes the change in
More informationPractice of Medicine-1 Ovarian Cancer Clinical Correlation
Practice of Medicine-1 Ovarian Cancer Clinical Correlation Amir A. Jazaeri, M.D. Assistant Professor, Division of Gynecologic Oncology American Cancer Society Female Cancers 2000 Statistics Reprinted by
More informationTargeted Therapies For Renal Cell Carcinoma
Targeted Therapies For Renal Cell Carcinoma If searched for the ebook Targeted Therapies for Renal Cell Carcinoma in pdf form, in that case you come on to the correct site. We presented utter option of
More informationRecent Developments in Research on Kidney Cancer: Highlights from Urological and Oncological Congresses in 2007
european urology supplements 7 (2008) 494 507 available at www.sciencedirect.com journal homepage: www.europeanurology.com Recent Developments in Research on Kidney Cancer: Highlights from Urological and
More informationCancer Program Report 2014
Cancer Program Report 2014 Queen of the Valley Hospital St Joseph Health Queen of the Valley Hospital - 2014 Site Table Site Total Class Sex Group Cases Analytic NonAn M F 0 I II ALL SITES 661 494 167
More informationCancer: recent advances and implications for underwriting
Cancer: recent advances and implications for underwriting Robert Rubens Select 74 Bristol 25 February 2010 Agenda Epidemiology - changing mortality Evidence-base for underwriting breast cancer ovarian
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationRenal cancer in adults
Renal cancer in adults Diagnosis, treatment and follow-up NADIA BENAHMED, JO ROBAYS, SABINE STORDEUR, THIERRY GIL, STEVEN JONIAU, NICOLAAS LUMEN, LAURETTE RENARD, SANDRINE RORIVE, DIRK SCHRIJVERS, BERTRAND
More informationCommon Questions about Cancer
6 What is cancer? Cancer is a group of diseases characterized by uncontrolled growth and spread of abnormal cells. The cancer cells form tumors that destroy normal tissue. If cancer cells break away from
More informationRenal tumors of adults
Renal tumors of adults Urinary Tract Tumors 2%-3% of all cancers in adults. The most common malignant tumor of the kidney is renal cell carcinoma. Tumors of the lower urinary tract are twice as common
More informationCANCER UROLOGY VOL. 12. P. S. Borisov 1, M. I. Shkol nik 2, R. V. Orlova 3, P. A. Karlov 1 DOI: /
CANCER UROLOGY 3 6 VOL. The use of targeted therapies and selection of the optimal treatment sequence in heterogeneous population of patients with metastatic kidney cancer. Results of retrospective study
More informationAllinaHealthSystems 1
Overview Biology and Introduction to the Genetics of Cancer Denise Jones, MS, CGC Certified Genetic Counselor Virginia Piper Cancer Service Line I. Our understanding of cancer the historical perspective
More informationCollection of Recorded Radiotherapy Seminars
IAEA Human Health Campus Collection of Recorded Radiotherapy Seminars http://humanhealth.iaea.org Conservative Treatment of Invasive Bladder Cancer Luis Souhami, MD Professor Department of Radiation Oncology
More informationInformation Services Division NHS National Services Scotland
Cancer in Scotland October 2012 First published in June 2004, revised with each National Statistics publication Next due for revision April 2013 Information Services Division NHS National Services Scotland
More informationPancreas Quizzes c. Both A and B a. Directly into the blood stream (not using ducts)
Pancreas Quizzes Quiz 1 1. The pancreas produces hormones. Which type of hormone producing organ is the pancreas? a. Endocrine b. Exocrine c. Both A and B d. Neither A or B 2. Endocrine indicates hormones
More informationRenal Cell Carcinoma: Status of Medical and Surgical Therapy. Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation
Renal Cell Carcinoma: Status of Medical and Surgical Therapy Ronald M. Bukowski Emeritus Physician Cleveland Clinic Foundation Metastatic Renal Cell Carcinoma: Evolution of Current Therapeutic Approaches
More informationEvidenze cliniche nel trattamento del RCC
Criteri di scelta nel trattamento sistemico del carcinoma renale Evidenze cliniche nel trattamento del RCC Alessandro Morabito Unità Sperimentazioni Cliniche Istituto Nazionale Tumori di Napoli Napoli,
More informationNegative Trials in RCC: Where Did We Go Wrong? Can We Do Better?
Negative Trials in RCC: Where Did We Go Wrong? Can We Do Better? 9 th European Kidney Cancer Symposium, Dublin, April 2014 Tim Eisen Tim Eisen - Disclosures Company Research Support Advisory Board Trial
More informationOncology 101. Cancer Basics
Oncology 101 Cancer Basics What Will You Learn? What is Cancer and How Does It Develop? Cancer Diagnosis and Staging Cancer Treatment What is Cancer? Cancer is a group of more than 100 different diseases
More informationInformation Services Division NHS National Services Scotland
Cancer in Scotland April 2013 First published in June 2004, revised with each National Statistics publication Next due for revision October 2013 Information Services Division NHS National Services Scotland
More informationI. Diagnosis of the cancer type in CUP
Latest Research: USA I. Diagnosis of the cancer type in CUP II. Outcomes of site-specific therapy of the cancer type in CUP a. Prospective clinical trial b. Retrospective clinical trials 1 Latest Research:
More informationTargeted Therapy in Advanced Renal Cell Carcinoma
Targeted Therapy in Advanced Renal Cell Carcinoma Brian I. Rini, M.D. Department of Solid Tumor Oncology Glickman Urologic and Kidney Institute Cleveland Clinic Taussig Cancer Institute Cleveland, Ohio
More information2016 Cancer Program Annual Report. Based on 2016 Cancer Program Activities and 2015 Cancer Registry Data
2016 Cancer Program Annual Report Based on 2016 Cancer Program Activities and 2015 Cancer Registry Data Presence Mercy Medical Center - Cancer Committee Cancer Committee Chairman Medical Oncology Mohammed
More informationNeoplasia part I. Dr. Mohsen Dashti. Clinical Medicine & Pathology nd Lecture
Neoplasia part I By Dr. Mohsen Dashti Clinical Medicine & Pathology 316 2 nd Lecture Lecture outline Review of structure & function. Basic definitions. Classification of neoplasms. Morphologic features.
More informationLANDMARK MEDICAL CENTER CANCER PROGRAM YEAR IN REVIEW 2013
LANDMARK MEDICAL CENTER CANCER PROGRAM YEAR IN REVIEW 2013 Landmark Medical Center offers a comprehensive cancer care services to our patients. LMC Cancer program is committed to ensure that patients receive
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Final appraisal determination Bevacizumab (first-line), sorafenib (first- and second-line),
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Final appraisal determination Bevacizumab (first-line), sorafenib (first- and secondline), sunitinib (second-line) and temsirolimus (firstline) for
More informationOverview of Hong Kong Cancer Statistics of 2015
Overview of Hong Kong Cancer Statistics of 2015 This report summarizes the key cancer statistics of Hong Kong for the year of 2015, which is now available on the website of Hong Kong Cancer Registry. Cancer
More informationAPPENDIX ONE: ICD CODES
APPENDIX ONE: ICD CODES ICD-10-AM ICD-9-CM Malignant neoplasms C00 C97 140 208, 238.6, 273.3 Lip, oral cavity and pharynx C00 C14 140 149 Digestive organs C15 C26 150 157, 159 Oesophagus 4 C15 150 excluding
More informationSequential Therapy in Renal Cell Carcinoma*
Sequential Therapy in Renal Cell Carcinoma* Bernard Escudier, MD, Marine Gross Goupil, MD, Christophe Massard, MD, and Karim Fizazi, MD, PhD Because of the recent approval of several drugs for the treatment
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More information1.The metastatic cascade. 2.Pathologic features of metastasis. 3.Therapeutic ramifications
Metastasis 1.The metastatic cascade 2.Pathologic features of metastasis 3.Therapeutic ramifications Sir James Paget (1814-1899) British Surgeon/ Pathologist Paget s disease of bone Paget s disease of the
More informationTreatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents
Conflict of Interest Treatment of Renal Cell Carcinoma (RCC) in the Era of Targeted Agents None Patrick Medina, PharmD, BCOP Associate Professor University of Oklahoma OKC, OK Learning Objectives Epidemiology
More informationKidney Case 1 SURGICAL PATHOLOGY REPORT
Kidney Case 1 Surgical Pathology Report February 9, 2007 Clinical History: This 45 year old woman was found to have a left renal mass. CT urography with reconstruction revealed a 2 cm medial mass which
More information2011 to 2015 New Cancer Incidence Truman Medical Center - Hospital Hill
Number of New Cancers Truman Medical Center Hospital Hill Cancer Registry 2015 Statistical Summary Incidence In 2015, Truman Medical Center diagnosed and/or treated 406 new cancer cases. Four patients
More informationCancer survival in Shanghai, China,
Cancer survival in Shanghai, China, 1992 1995 Xiang YB, Jin F and Gao YT Abstract The Shanghai cancer registry, established in 1963, is the oldest one in mainland China; cancer registration is entirely
More informationJohn Fitzpatrick Memorial Lecture. John Fitzpatrick Memorial lecture
John Fitzpatrick Memorial Lecture John Fitzpatrick Memorial Lecture John M Fitzpatrick, 1948 2014 Head of Research at the Irish Cancer Society Professor of Surgery and Consultant Urologist at the Mater
More informationFrancisco Socola, Arturo Loaiza-Bonilla, and Pasquale Benedetto
Hindawi Publishing Corporation Case Reports in Oncological Medicine Volume 2012, Article ID 390702, 5 pages doi:10.1155/2012/390702 Case Report Axitinib Induced Recurrent Pneumothorax following Near-Complete
More informationThe Future of Cancer. Lawrence Tsui Global Risk Products Actuary Swiss Reinsurance Company Hong Kong. Session Number: WBR8
Lawrence Tsui Global Risk Products Actuary Swiss Reinsurance Company Hong Kong Session Number: WBR8 Agenda Cancer the basics Cancer past and present Cancer the future CANCER THE BASICS Cancer the basics
More informationCLINICAL POLICY Department: Medical Management Document Name: Inlyta Reference Number: NH.PHAR.100 Effective Date: 05/12
Page: 1 of 5 IMPORTANT REMINDER This Clinical Policy has been developed by appropriately experienced and licensed health care professionals based on a thorough review and consideration of generally accepted
More informationUNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL. PhD THESIS
UNIVERSITY OF MEDICINE AND PHARMACY CRAIOVA PhD SCHOOL PhD THESIS THE IMPORTANCE OF TUMOR ANGIOGENESIS IN CEREBRAL TUMOR DIAGNOSIS AND THERAPY ABSTRACT PhD COORDINATOR: Prof. univ. dr. DRICU Anica PhD
More informationWinship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients
Winship Cancer Institute of Emory University Neoadjuvant Systemic Therapy in Metastatic Renal Cell Carcinoma Patients Bradley Carthon, MD, PhD Assistant Professor, Genitourinary Medical Oncology Winship
More informationCytoreductive Nephrectomy
Cytoreductive Nephrectomy Stephen H. Culp, M.D., Ph.D. Assistant Professor, Department of Urology Outline The Historics of CN The current status of CN The importance of patient selection Cytoreductive
More informationMaram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine
Maram Abdaljaleel, MD Dermatopathologist and Neuropathologist University of Jordan, School of Medicine The most common non-skin malignancy of women 2 nd most common cause of cancer deaths in women, following
More informationCancer survival in Seoul, Republic of Korea,
Cancer survival in Seoul, Republic of Korea, 1993 1997 Ahn YO and Shin MH Abstract The Seoul cancer registry was established in 1991. Cancer is a notifiable disease, and registration of cases is done by
More informationWilms Tumor and Neuroblastoma
Wilms Tumor and Neuroblastoma Wilm s Tumor AKA: Nephroblastoma the most common intra-abdominal cancer in children. peak incidence is 2 to 3 years of age Biology somatic mutations restricted to tumor tissue
More informationManagement of High Risk Renal Cell Carcinoma
Management of High Risk Renal Cell Carcinoma Peter E. Clark, MD Professor and Chair, Department of Urology Carolinas HealthCare System Chair, Urologic Oncology Levine Cancer Institute October 14, 2017
More informationOverview of Cancer. Mylene Freires Advanced Nurse Practitioner, Haematology
Overview of Cancer Mylene Freires Advanced Nurse Practitioner, Haematology Aim of the Presentation Review basic concepts of cancer Gain some understanding of the socio-economic impact of cancer Order of
More informationCHAPTER 10 CANCER REPORT. Jeremy Chapman. and. Angela Webster
CHAPTER 10 CANCER REPORT Jeremy Chapman and Angela Webster CANCER REPORT ANZDATA Registry 2004 Report This report summarises the cancer (excluding nonmelanocytic skin cancer) experience of patients treated
More informationBaker Alabbadi MD*, Ali Alasmar MD*, Ayman Alqarallah MD*, Nizar Saaydah MD* ABSTRACT
Renal Cell Carcinoma Clinical Presentation and Histopathological Findings: A Retrospective Analysis of a Jordanian Population at King Hussein Medical Center Baker Alabbadi MD*, Ali Alasmar MD*, Ayman Alqarallah
More informationOutcomes Report: Accountability Measures and Quality Improvements
Outcomes Report: Accountability Measures and Quality Improvements The s Cancer Committee ensures that patients with cancer are treated according to the nationally accepted measures. Because we are an accredited
More informationNCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Kidney Cancer. Version February 6, NCCN.org.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Version 3.2018 February 6, 2018 NCCN.org NCCN Guidelines for Patients available at www.nccn.org/patients Continue Version 3.2018, 02/06/18
More informationSubject: Axitinib (Inlyta ) Tablets
09-J1000-67 Original Effective Date: 05/15/12 Reviewed: 12/12/18 Revised: 01/15/19 Subject: Axitinib (Inlyta ) Tablets THIS MEDICAL COVERAGE GUIDELINE IS NOT AN AUTHORIZATION, CERTIFICATION, EXPLANATION
More information